Search results for "THROMBOSIS"

showing 10 items of 630 documents

Transarterielle Chemoembolisation (TACE) des Hepatozellulären Karzinoms (HCC) bei Patienten mit Pfortaderthrombose - Erfahrungen

2007

PURPOSE: Comparative analysis of the course of disease in patients with initial diagnosis of portal vein thrombosis in HCC treated with sequential TACE. Evaluation of the efficacy and safety of the method in a selected patient cohort. PATIENTS AND METHODS: The study included 22 patients with HCC that were palliatively treated at least 3 times with TACE. All patients presented a portal vein thrombosis in the initial CT investigation. The TACE-procedure was carried out in regular intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10-20 ml Lipiodol. Follow-up investigations were carried out with contrast enhanced Multislice-CT before and after TACE and control…

medicine.medical_specialtyPalliative carebusiness.industryRetrospective cohort studymedicine.diseaseThrombosisGastroenterologyPortal vein thrombosisInternal medicineHepatocellular carcinomamedicineLipiodolSurgeryLiver functionRadiologybusinessContraindicationmedicine.drugZentralblatt für Chirurgie
researchProduct

Atherosclerosis, inflammation and Chlamydia pneumoniae

2009

Coronary heart disease is the single most common cause of illness and death in the developed world. Coronary atherosclerosis is by far the most frequent cause of ischemic heart disease, and plaque disruption with superimposed thrombosis is the main cause of the acute coronary syndromes of unstable angina, myocardial infarction, and sudden death. Atherosclerosis is the result of a complex interaction between blood elements, disturbed flow, and vessel wall abnormality, involving several pathological processes: inflammation, with increased endothelial permeability, endothelial activation, and monocyte recruitment; growth, with smooth muscle cell proliferation, migration, and matrix synthesis; …

medicine.medical_specialtyPathologyATHEROSCLEROSIS INFECTIONUnstable anginabusiness.industryInflammationChlamydia Coronary atherosclerosis Coronary heart disease PhlogosisReviewmedicine.diseaseSudden deathThrombosisEndothelial activationInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessCoronary atherosclerosisCalcification
researchProduct

Benign intracranial hypertension associated to blood coagulation derangements

2006

Abstract Background Benign Intracranial Hypertension (BIH) may be caused, at least in part, by intracranial sinus thrombosis. Thrombosis is normally due to derangements in blood coagulation cascade which may predispose to abnormal clotting activation or deficiency in natural inhibitors' control. The aim of the study is to examine the strength of the association between risk factors for thrombosis and BIH. Patients and methods The incidence of prothrombotic abnormalities among a randomly investigated cohort of 17 patients with BIH, was compared with 51 healthy subjects matched for sex, age, body mass index, height and social background. Results The number of subjects with protein C deficienc…

medicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologysymbols.namesakeProtein C deficiencyIntracranial hypertension blood coagulation fibrinolysisInternal medicineFibrinolysismedicineFisher's exact testAngiologyHematologybiologylcsh:RC633-647.5business.industrylcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseThrombosisMethylenetetrahydrofolate reductasesymbolsbiology.proteinOriginal Clinical InvestigationbusinessBody mass index
researchProduct

ABSORB everolimus-eluting bioresorbable vascular scaffold systems for the sealing of unstable plaques

2013

Purpose: We set out to investigate the outcome of patients receiving an Absorb bioresorbable vascular scaffold system in the setting of acute coronary syndromes. Background: Everolimus-eluting bioresorbable vascular scaffold systems have recently been introduced in the market for the treatment of coronary artery stenoses. Experience on the use of these devices is limited to type A lesions in elective settings. Treatment of ruptured plaques with bioresorbable scaffold systems might have the advantage to promote the formation of new fibrotic tissue (plaque sealing) without the disadvantages of permanent metal stent implantation. Methods and results: 64 culprit lesions in 63 patients (age 57±1…

medicine.medical_specialtyPercutaneousUnstable anginabusiness.industrymedicine.medical_treatmentStentmedicine.diseaseThrombosisCulpritSurgerymedicine.anatomical_structureInternal medicinemedicineCardiologyCircumflexMyocardial infarctionCardiology and Cardiovascular MedicinebusinessArteryEuropean Heart Journal
researchProduct

Percutaneous Femoropopliteal Bypass: 2-Year Results of the DETOUR System

2021

Purpose: This study investigated the 2-year safety and effectiveness of the PQ Bypass DETOUR system as a percutaneous femoropopliteal bypass. Materials and Methods: Seventy-eight patients with 82 long-segment femoropopliteal lesions were enrolled in this prospective, single-arm, multicenter study. The DETOUR system deployed Torus stent grafts directed through a transvenous route. Eligible patients included those with lesions of >10 cm and average of 371±55 mm. Key safety endpoints included major adverse events (MAEs) and symptomatic deep venous thrombosis in the target limb. Effectiveness endpoints included primary patency defined as freedom from ≥50% stenosis, occlusion, or clinically-d…

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentLesionPeripheral Arterial DiseaseOcclusionmedicineHumansPopliteal ArteryRadiology Nuclear Medicine and imagingProspective StudiesAdverse effectVascular Patencybusiness.industryEndovascular ProceduresStentmedicine.diseaseSurgeryFemoral ArteryVenous thrombosisStenosisTreatment OutcomeStentsSurgerymedicine.symptomCardiology and Cardiovascular MedicinebusinessClaudicationJournal of Endovascular Therapy
researchProduct

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R …

2019

The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 &plusmn

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinlcsh:Medicine030204 cardiovascular system & hematologyKoronare HerzkrankheitRevascularizationAbsorbable implantsCoronary artery diseaseArticleCoronary artery diseasedrug eluting stents03 medical and health sciences0302 clinical medicineDrug-eluting StentMedizinische Fakultätstent bioresorbableMedicine030212 general & internal medicineMyocardial infarctionddc:610Drug-eluting stentsTissue scaffoldsEverolimusbusiness.industrylcsh:RStentGeneral Medicinemedicine.diseaseThrombosisSurgeryConventional PCIbusinessDDC 610 / Medicine & healthcoronary artery diseasemedicine.drugJournal of Clinical Medicine
researchProduct

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregna…

2021

Abstract Myeloproliferative neoplasms (MPN) are traditionally regarded as a disease of older adults, though a not negligible fraction of cases occurs at a younger age, including women of childbearing potential. MPN in younger patients, indeed, offer several challenges for the clinical hematologist, that goes from difficulties in reaching a timely and accurate diagnosis to a peculiar thrombotic risk, with a relatively high incidence of thromboses in unusual sites (as the splanchnic veins or the cerebral ones). Moreover, the issue of pregnancy is recently gaining more attention as maternal age is rising and molecular screening are widely implemented, leading to a better recognition of these c…

medicine.medical_specialtyPhiladelphia Chromosome NegativeMyeloproliferative neoplasmDiseaseEssential thrombocythemiaCritical discussionMyeloproliferative neoplasmsAntiphospholipid syndromePregnancyNeoplasmsmedicineHumansPhiladelphia ChromosomeHematologistIntensive care medicineAgedEssential thrombocythemia; Myeloproliferative neoplasms; PregnancyPregnancyMyeloproliferative DisordersEssential thrombocythemiabusiness.industryIncidencefood and beveragesThrombosisHematologymedicine.diseaseOncologyYounger adultsFemalebusinessmanagement
researchProduct

Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias an…

2012

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases th…

medicine.medical_specialtyPhysiologymacromolecular substancesFibrosisRisk FactorsCardiovascular DisorderInternal medicineThromboembolismAtrial FibrillationInternal MedicinemedicineHumanscardiovascular diseasesRisk factorStrokeSocieties Medicalbusiness.industryWarfarinAtrial fibrillationHypertension atrial fibrillation anticoagulants antihypertensive treatmentMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseThrombosisEuropeBlood pressureHypertensionCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Thrombosis

2014

Background— Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective— To review the literature on the global burden of disease caused by VTE. Approach and Results— We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded…

medicine.medical_specialtyPopulation ageingPopulationMyocardial IschemiaDisease030204 cardiovascular system & hematologyGlobal HealthCohort Studies03 medical and health sciencesLife Expectancy0302 clinical medicineCost of IllnessCause of DeathEnvironmental healthGlobal healthPrevalenceHumansMedicinecardiovascular diseases030212 general & internal medicineIntensive care medicineeducationStrokeDisease burdenCause of deathVenous Thrombosiseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Racial GroupsAge FactorsThrombosisVenous ThromboembolismHematologymedicine.diseaseThrombosis3. Good healthStrokePneumoniaVenous thrombosisSocial ClassQuality-Adjusted Life YearsMedical emergencyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct